Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Breast Neoplasms 1223Neoplasms 1041Carcinoma, Non-Small-Cell Lung 755Prostatic Neoplasms 693Colorectal Neoplasms 593Lung Neoplasms 574Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 399Neoplasm Metastasis 387Multiple Myeloma 374Ovarian Neoplasms 372Stomach Neoplasms 317Carcinoma, Hepatocellular 303Melanoma 282Recurrence 281Brain Neoplasms 281Squamous Cell Carcinoma of Head and Neck 268Head and Neck Neoplasms 237Endometrial Neoplasms 235Glioblastoma 234Triple Negative Breast Neoplasms 230Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Uterine Cervical Neoplasms 225Lymphoma 224Hematologic Neoplasms 200Sarcoma 199Urinary Bladder Neoplasms 197Esophageal Neoplasms 191Carcinoma, Renal Cell 190Lymphoma, Non-Hodgkin 176

Interventions

fludarabine phosphate 1Specimen Handling 1Leukapheresis 1Cyclophosphamide 1Blood Component Removal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Prolymphocytic, B-Cell × 1 year × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT02863692 2025-12-08

CLL-Registry

German CLL Study Group

Recruiting
8,000 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡